Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls
- PMID: 32113908
- PMCID: PMC7327519
- DOI: 10.1016/j.bbi.2020.02.010
Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls
Abstract
Importance: The magnitude and variability of cytokine alterations in depression are not clear.
Objective: To perform an up to date meta-analysis of mean differences of immune markers in depression, and to quantify and test for evidence of heterogeneity in immune markers in depression by conducting a meta-analysis of variability to ascertain whether only a sub-group of patients with depression show evidence of inflammation.
Data sources: Studies that reported immune marker levels in peripheral blood in patients with depression and matched healthy controls in the MEDLINE database from inception to August 29th 2018 were examined.
Study selection: Case-control studies that reported immune marker levels in peripheral blood in patients with depression and healthy controls were selected.
Data extraction and synthesis: Means and variances (SDs) were extracted for each measure to calculate effect sizes, which were combined using multivariate meta-analysis.
Main outcomes and measures: Hedges g was used to quantify mean differences. Relative variability of immune marker measurements in patients compared with control groups as indexed by the coefficient of variation ratio (CVR).
Results: A total of 107 studies that reported measurements from 5,166 patients with depression and 5,083 controls were included in the analyses. Levels of CRP (g = 0.71; 95%CI: 0.50-0.92; p < 0.0001); IL-3 (g = 0.60; 95%CI: 0.31-0.89; p < 0.0001); IL-6 (g = 0.61; 95%CI: 0.39-0.82; p < 0.0001); IL-12 (g = 1.18; 95%CI: 0.74-1.62; p < 0.0001); IL-18 (g = 1.97; 95%CI: 1.00-2.95; p < 0.0001); sIL-2R (g = 0.71; 95%CI: 0.44-0.98; p < 0.0001); and TNFα (g = 0.54; 95%CI: 0.32-0.76; p < 0.0001) were significantly higher in patients with depression. These findings were robust to a range of potential confounds and moderators. Mean-scaled variability, measured as CVR, was significantly lower in patients with depression for CRP (CVR = 0.85; 95%CI: 0.75-0.98; p = 0.02); IL-12 (CVR = 0.61; 95%CI: 0.46-0.80; p < 0.01); and sIL-2R (CVR = 0.85; 95%CI: 0.73-0.99; p = 0.04), while it was unchanged for IL-3, IL-6, IL-18, and TNF α.
Conclusions and relevance: Depression is confirmed as a pro-inflammatory state. Some of the inflammatory markers elevated in depression, including CRP and IL-12, show reduced variability in patients with depression, therefore supporting greater homogeneity in terms of an inflammatory phenotype in depression. Some inflammatory marker elevations in depression do not appear due to an inflamed sub-group, but rather to a right shift of the immune marker distribution.
Keywords: CRP; Cytokine; Depression; Heterogeneity; Inflammation; Meta-analysis.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7327519/bin/gr1.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7327519/bin/gr2.gif)
Similar articles
-
Peripheral levels of C-reactive protein, tumor necrosis factor-��, interleukin-6, and interleukin-1β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability.Brain Behav Immun. 2021 Oct;97:193-203. doi: 10.1016/j.bbi.2021.07.014. Epub 2021 Jul 28. Brain Behav Immun. 2021. PMID: 34332041
-
Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A Meta-analysis.JAMA Psychiatry. 2017 Nov 1;74(11):1104-1111. doi: 10.1001/jamapsychiatry.2017.2663. JAMA Psychiatry. 2017. PMID: 28973084 Free PMC article.
-
Aberrations in Peripheral Inflammatory Cytokine Levels in Parkinson Disease: A Systematic Review and Meta-analysis.JAMA Neurol. 2016 Nov 1;73(11):1316-1324. doi: 10.1001/jamaneurol.2016.2742. JAMA Neurol. 2016. PMID: 27668667 Review.
-
A Meta-analysis of Immune Parameters, Variability, and Assessment of Modal Distribution in Psychosis and Test of the Immune Subgroup Hypothesis.Schizophr Bull. 2019 Sep 11;45(5):1120-1133. doi: 10.1093/schbul/sby160. Schizophr Bull. 2019. PMID: 30407606 Free PMC article.
-
Adiponectin, TNF-α and inflammatory cytokines and risk of type 2 diabetes: A systematic review and meta-analysis.Cytokine. 2016 Oct;86:100-109. doi: 10.1016/j.cyto.2016.06.028. Epub 2016 Aug 4. Cytokine. 2016. PMID: 27498215 Review.
Cited by
-
Use of Extracellular Monomeric Ubiquitin as a Therapeutic Option for Major Depressive Disorder.Pharmaceuticals (Basel). 2024 Jun 27;17(7):841. doi: 10.3390/ph17070841. Pharmaceuticals (Basel). 2024. PMID: 39065692 Free PMC article.
-
Differentiating Stages of Bipolar and Unipolar Depression-The Possible Role of sICAM-1 and sVCAM-1.Cells. 2024 Jul 18;13(14):1213. doi: 10.3390/cells13141213. Cells. 2024. PMID: 39056795 Free PMC article.
-
Immunometabolic Blood Biomarkers of Developmental Trajectories of Depressive Symptoms: Findings From the ALSPAC Birth Cohort.medRxiv [Preprint]. 2024 Jul 12:2024.07.12.24310330. doi: 10.1101/2024.07.12.24310330. medRxiv. 2024. PMID: 39040209 Free PMC article. Preprint.
-
Antibiotic or gastric acid inhibitor use during pregnancy and postpartum depression: Population-based cohort study.Acta Obstet Gynecol Scand. 2024 Aug;103(8):1596-1605. doi: 10.1111/aogs.14864. Epub 2024 Jun 3. Acta Obstet Gynecol Scand. 2024. PMID: 38831623 Free PMC article.
-
Inflammation and immune system pathways as biological signatures of adolescent depression-the IDEA-RiSCo study.Transl Psychiatry. 2024 Jun 1;14(1):230. doi: 10.1038/s41398-024-02959-z. Transl Psychiatry. 2024. PMID: 38824135 Free PMC article.
References
-
- Maes M., Fi��ar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. Inflammopharmacol. 2012;20(3):127–150. - PubMed
-
- Benros M.E., Waltoft B.L., Nordentoft M., Østergaard S.D., Eaton W.W., Krogh J. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMAPsychiatry. 2013;70(8):812–820. - PubMed
-
- Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine. 2009;71(2):171–186. - PubMed
-
- Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K. A meta-analysis of cytokines in major depression. Biol. Psychiatry. 2010;67(5):446–457. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous